|
|
 |
|
Viewing report
|
|
|
|
The Outlook For RNAi: Accelerating Drug Discovery and the Development of RNAi Therapeutics
Business Insights, May 2005
While the human genome project has provided vast amounts of sequence information, the in vivo functional analysis of thousands of genes has presented a significant challenge to researchers and to pharmaceutical companies in the discovery of new drug targets. However, RNAi-based screens have provided new opportunities for the discovery and validation of novel therapeutic targets in several disease areas such as cancer and infectious diseases.
The RNAi market achieved global sales of just over $1bn in 2004 and is projected to reach $2.5bn by 2010, a compound annual growth rate (CAGR) 2004-2010 of 14%.
'The Outlook for RNAi: Accelerating Drug Discovery and the Development of RNAi Therapeutics' is a new management report which analyzes the latest trends in the RNAi market, allowing pharmaceutical companies to decide which areas of RNAi technologies to invest in, to improve drug attrition rates and develop new therapeutic agents. RNAi therapeutics are forecast to generate sales of around $1bn by 2015 and this market has significant potential, should companies be able to overcome delivery constraints.
This report analyzes future trends of RNAi and provides detailed insight into the most effective use of this novel technology in the drug discovery process. This report details recent alliances and acquisitions being made by big pharmaceutical companies, allowing you to assess their investment in this new and rapidly advancing field.
Key Features:
- Value and breakdown of sub-sector performances of the RNAi market 2004-2015
- In-depth examination of key companies involved in the development of RNAi therapeutics, key therapy areas, the phase of clinical development, potential drug sales and patent position
- Analysis of the strengths and weaknesses of different approaches to RNAi delivery and selectivity
- Future direction of RNAi research and the development of second generation siRNAs, miRNAs and multifunctional siRNAs
Key Findings:
- The two key challenges to RNAi-based therapies are ensuring efficient drug delivery and avoiding 'off-target' gene suppression.
- RNAi-based screens have provided new opportunities for the discovery and validation of novel therapeutic targets and offer new hope for 'smarter targets', ultimately having a significant effect on the drug development process and drug attrition rates.
- Companies are already developing 'second generation' gene silencing agents including: multifunctional siRNAs, hyperfunctional or superactive siRNAs, no-ribose siNAs and siRNAs conjugated with small molecule drugs, which may have critical advantages over their predecessors.
About the author
Dr CL Barton has over 10 years practical pharmaceutical research experience with a leading pharmaceutical company and Pan-European Pharmaceutical analyst with a
European Bank.
Dr CL Barton Ltd. aims to provide independent, tailor-made, pharmaceutical thematic research to investment houses. Where applicable the research reports combine independent scientific analysis with patients- and prescription-based models to forecast the potential sales growth of key developmental drugs and isolate the key drivers within the pharmaceutical sector.
|
|
|
|
